Share-based Payment Arrangement, Expense of Arcturus Therapeutics Holdings Inc. from 30 Jun 2018 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Arcturus Therapeutics Holdings Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2018 to 31 Dec 2025.
  • Arcturus Therapeutics Holdings Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $6,817,000, a 24% decline year-over-year.
  • Arcturus Therapeutics Holdings Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $25,408,000, a 33% decline year-over-year.
  • Arcturus Therapeutics Holdings Inc. annual Share-based Payment Arrangement, Expense for 2025 was $25,408,000, a 33% decline from 2024.
  • Arcturus Therapeutics Holdings Inc. annual Share-based Payment Arrangement, Expense for 2024 was $37,988,000, a 9.6% increase from 2023.
  • Arcturus Therapeutics Holdings Inc. annual Share-based Payment Arrangement, Expense for 2023 was $34,649,000, a 13% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Arcturus Therapeutics Holdings Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $25,408,000 $6,817,000 -$2,166,000 -24% 01 Oct 2025 31 Dec 2025 10-K 03 Mar 2026 2025 FY
Q3 2025 $27,574,000 $5,729,000 -$3,764,000 -40% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $31,338,000 $6,200,000 -$3,224,000 -34% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $34,562,000 $6,662,000 -$3,426,000 -34% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $37,988,000 $8,983,000 +$168,000 +1.9% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2026 2025 FY
Q3 2024 $37,820,000 $9,493,000 +$224,000 +2.4% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $37,596,000 $9,424,000 +$1,041,000 +12% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $36,555,000 $10,088,000 +$1,906,000 +23% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $34,649,000 $8,815,000 +$2,285,000 +35% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2026 2025 FY
Q3 2023 $32,364,000 $9,269,000 -$167,000 -1.8% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $32,531,000 $8,383,000 +$1,109,000 +15% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 $31,422,000 $8,182,000 +$811,000 +11% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $30,611,000 $6,530,000 -$988,000 -13% 01 Oct 2022 31 Dec 2022 10-K 06 Mar 2025 2024 FY
Q3 2022 $31,599,000 $9,436,000 +$2,566,000 +37% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $29,033,000 $7,274,000 -$266,000 -3.5% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $29,299,000 $7,371,000 +$384,000 +5.5% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $28,915,000 $7,518,000 +$4,692,000 +166% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2024 2023 FY
Q3 2021 $24,223,000 $6,870,000 +$4,882,000 +246% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $19,341,000 $7,540,000 +$6,439,000 +585% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $12,902,000 $6,987,000 +$6,138,000 +723% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $6,764,000 $2,826,000 +$2,029,000 +255% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $4,735,000 $1,988,000 +$1,605,000 +419% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $3,130,000 $1,101,000 +$698,000 +173% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $2,432,000 $849,000 +$450,000 +113% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $1,982,000 $797,000 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $383,000 -$204,000 -35% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $403,000 +$263,000 +188% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $399,000 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q3 2018 $587,000 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $140,000 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2

Arcturus Therapeutics Holdings Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $25,408,000 -$12,580,000 -33% 01 Jan 2025 31 Dec 2025 10-K 03 Mar 2026 2025 FY
2024 $37,988,000 +$3,339,000 +9.6% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2026 2025 FY
2023 $34,649,000 +$4,038,000 +13% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2026 2025 FY
2022 $30,611,000 +$1,696,000 +5.9% 01 Jan 2022 31 Dec 2022 10-K 06 Mar 2025 2024 FY
2021 $28,915,000 +$22,151,000 +327% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2024 2023 FY
2020 $6,764,000 +$4,782,000 +241% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
2019 $1,982,000 +$723,000 +57% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $1,259,000 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.